We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+10.75%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3B
AUM Growth
-$85.7M
Cap. Flow
-$518M
Cap. Flow %
-17.24%
Top 10 Hldgs %
35.54%
Holding
152
New
30
Increased
26
Reduced
33
Closed
32

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$60.8M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$55.6M
3
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$40.9M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$39.9M
5
DYAX
DYAX CORPORATION
DYAX
+$35.8M

Top Sells

Rank Stock Value
1
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$446M
2
ABBV icon
AbbVie
ABBV
+$89.8M
3
ADVM
Adverum Biotechnologies
ADVM
+$85.8M
4
BLUE
bluebird bio
BLUE
+$47.9M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$27.7M

Sector Composition

Rank Sector Weight
1 Healthcare 70.77%
2 Financials 3.42%
3 Technology 0.52%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CSCI
126
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
– –
-90
Closed -$482K
TVRD
127
Tvardi Therapeutics
TVRD
$26.7M
– –
-13,155
Closed -$4.76M
ARAV
128
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-56,617
Closed -$6.24M
AGRX
129
DELISTED
Agile Therapeutics
AGRX
– –
-53
Closed -$973K
HMSY
130
DELISTED
HMS Holdings Corp.
HMSY
– –
-29,900
Closed -$462K
IMMU
131
CALL
DELISTED
Immunomedics Inc
IMMU
– –
-500,000
Closed -$1.92M
ACHN
132
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-2,810,164
Closed -$27.7M
KERX
133
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-765,450
Closed -$9.74M
CASC
134
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-23,867
Closed -$233K
SCMP
135
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
– –
-225,000
Closed -$3.5M
TRIV
136
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
– –
-990,202
Closed -$10.4M
LMNS
137
DELISTED
LUMENIS LTD CL B ORD SHS (ISR)
LMNS
– –
-434,566
Closed -$5.2M
IMRS
138
DELISTED
IMRIS INC COMMON SHARES (CANADA)
IMRS
– –
-147,076
Closed -$141K
ASPX
139
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
– –
-4,449,103
Closed -$446M
CELG
140
DELISTED
Celgene Corp
CELG
– –
-3,500
Closed -$403K
PARN
141
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
– –
-253,592
Closed -$1.25M
2 3 4 5
6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2015 Portfolio in Review

As of Q2 2015, Deerfield Management held 152 positions worth $3B, down 2.8% from $3.09B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Deerfield Management withdrew a net $518M in Q2 2015, closing 32 positions and reducing 33 holdings. Its most notable exit was AUSPEX PHARMACEUTICALS INC COM STK (DE), an estimated $446M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 60% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Alpine Immune Sciences Inc worth $56.5M.

  • Deerfield Management's largest Q2 2015 buy was Alpine Immune Sciences Inc: 933,103 shares worth $56.5M.
  • Deerfield Management added most to Viatris in Q2 2015, an estimated $60.8M increase.
  • Deerfield Management's biggest Q2 2015 reduction was bluebird bio, cutting an estimated $47.9M.
  • Deerfield Management fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2015, selling an estimated $446M.
  • Deerfield Management's ten largest holdings make up 36% of its $3B portfolio in Q2 2015.
  • Deerfield Management opened 30 new positions and closed 32 in Q2 2015.
  • Deerfield Management's portfolio value fell 2.8% quarter-over-quarter to $3B.

Based on Deerfield Management's 13F filing for Q2 2015, filed 14 Aug 2015.